Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/14/2008

rior to AIDS virus infection. The

vaccine regimen employs a two-vaccine "prime-boost strategy." Trial

participants will be administered GeoVax HIV-1 DNA vaccine which

"primes" the immune system followed by GeoVax's HIV-1 MVA (Modified

Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus

components but can not cause AIDS. Safety and immunological results

from earlier as well as ongoing human trials are very encouraging thus

supporting planned acceleration of large scale Phase 2 clinical

studies.

-- In September, GeoVax announced receipt of an estimated $15 million

Integrated Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant

to support its HIV/AIDS vaccine program. This large Grant was awarded

by the National Institutes of Health-National Institute of Allergy &

Infectious Disease [NIH-NIAID], an agency of the U.S. Government. The

grant funding period is over a five year period commencing October

2007. Only meritorious HIV/AIDS prevention vaccine candidates are

considered to receive an IPCAVD award. Candidate companies are highly

scrutinized and must supply substantial positive AIDS vaccine data to

support their application. IPCAVD grants are awarded on a competitive

basis and are designed to support later stage vaccine research,

development and human trials. GeoVax will utilize this funding to

further its HIV/AIDS vaccine development, optimization, production and

human clinical trial testing.

GeoVax announced in January 2008 that it had been recognized by Georgia

Bio, the state trade organization, as a 2007 "Deal of the Year" award

winner for receipt of the $15 million IPCAVD grant.

-- In September, GeoVax announced the presentation of successful human

trial results for its HIV/AIDS vaccines at the
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
2. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
6. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
10. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
11. PLC Systems Reports Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... , March 17 Access MediQuip, LLC, the nation,s first and largest provider ... enhanced its proprietary Recall Management Service, "RMS," for its customers nationwide. The new release is ... while managing cost. , ... ...
(Date:3/17/2010)... CAMBRIDGE, Mass. , March 17 ... community for physicians, today announced the results of ... Therapies: Physicians Social Media Conversations. " The report ... blood clotting, anticoagulation, anti-platelet, and thrombolytic treatments. According ...
(Date:3/17/2010)... , March 17 Endo Pharmaceuticals (Nasdaq: ENDP ) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference ... products and development programs. , ... , , ... ...
Breaking Medicine Technology:Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 2Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 3Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 2Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 3Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point 4Endo to Present at Barclays Capital Global Healthcare Conference 2Endo to Present at Barclays Capital Global Healthcare Conference 3Adamari Lopez 26 Yoplait 28R 29 Committed to Continue Raising Awareness for Breast Cancer Risk Reduction Among the Hispanic Community 57192 1Adamari Lopez 26 Yoplait 28R 29 Committed to Continue Raising Awareness for Breast Cancer Risk Reduction Among the Hispanic Community 57192 2Adamari Lopez 26 Yoplait 28R 29 Committed to Continue Raising Awareness for Breast Cancer Risk Reduction Among the Hispanic Community 57192 3Caraco Pharmaceutical Laboratories Ltd Announces Appointment of F Folsom Bell to Board of Directors 57189 1Caraco Pharmaceutical Laboratories Ltd Announces Appointment of F Folsom Bell to Board of Directors 57189 2Caraco Pharmaceutical Laboratories Ltd Announces Appointment of F Folsom Bell to Board of Directors 57189 3Genomas Awarded 241 4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness 14058 1Genomas Awarded 241 4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness 14058 2
... of Disease on Work Status and,Productivity, WASHINGTON, May ... Disease Week(R) 2007 (DDW), from,long-term extensions of the ... that subjects with moderately to severely active,ulcerative colitis ... blinded phase of the trials maintained,improvement in their ...
... Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical,company, ... sponsored by,the Company has been accepted for ... 67th Scientific Sessions in Chicago.,The abstract, entitled ... Study of Intranasal Insulin Spray,(Nasulin(TM)) and Injectable ...
Other Medicine Technology:Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3
(Date:3/21/2010)... 21, 2010 With stomach irritation preventing almost 2 ... today reported discovery of several substances that may be ... stomach pain in every cup. , Their report, ... American Chemical Society, included the counter-intuitive finding that espresso, ... on the tummy because these roasts contain a substance ...
(Date:3/21/2010)... WASHINGTON , March 21 Phyllis Schlafly , president and founder of the conservative grassroots public policy organization Eagle Forum, made the ... today in the House: , ... , , ... ... ...
(Date:3/21/2010)... NEW YORK , March 21 President Barack Obama ... health bill with promises that he will "fix" their fears of abortion funding ... Court made that clear in Youngstown Sheet & Tube Company v. Sawyer , ... ... ...
(Date:3/21/2010)... first time in humans, scientists used RNA to ... March 21 (HealthDay News) -- For the first ... gene-manipulation therapy to enter tumor cells and block ... cancer, researchers report. , "They,re basically putting ... don,t want this protein expressed for now," explained ...
(Date:3/18/2010)... ... events – it can actually take a toll on health, according to a new study ... ... impact the way people perceive negative events – it can actually take a toll on ...
Breaking Medicine News(10 mins):Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 2Health News:Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient 3Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 3Health News:Betsy McCaughey Says Anti-Abortion Democrats Should not be Hoodwinked by President's Promise of Executive Order 'Fix' 2Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 2Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 3Health News:Low Self-Esteem Can Threaten Health, Online Dating Study Finds 2Health News:Low Self-Esteem Can Threaten Health, Online Dating Study Finds 3
... open their doors,Wednesday to Trick or Treaters and the ... Oct. 30 It,s not every day,pirates and gypsies ... witches and 3-foot tall bumblebees, and little goblins rarely,get ... more,than 150 nursing homes in California this Halloween, it,s ...
... LONDON, Oct. 30 Chiltern, a leading global ... Clinical,Trial Management Services, Inc. (CTMS) a Bristol, Tennessee ... States. From February,2008 the combined operation will be ... by Dr. Robert Vann, John Vann and Ben ...
... the worlds largest society for molecular imaging and nuclear ... Tuesdays Roll Call urging Congress to fund basic nuclear ... discoveries. Support DOE funding for nuclear medicine research, notes ... news of legislative and political interest to Capitol Hill ...
... face increasingly large-scale,health risks from our expanding impact ... extremes and dengue fever to obesity, diabetes and ... medical researchers have contributed to a new,report which ... increasing,risks to the health of Australians., Released today ...
... limiting bariatric surgeries to high-volume centers disproportionately restrict ... are among the most in need of them, ... researchers shows. , Government-imposed restrictions currently mandate a ... bariatric surgeries under Medicare and Medicaid because some ...
... Fiscal Year EPS Outlook for One-time Tax Benefit, ... (NYSE: PG ) announced net sales growth of ... segment delivered,mid-single digit or higher sales growth. Organic sales ... company,s four to six percent target,growth range. The Fabric ...
Other Medicine News:Health News:Halloween Events in Eureka, California Bring Young and Old Together for a Ghoulish Good Time 2Health News:Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc. 2Health News:SNM ad urges congress to fund nuclear medicine research 2Health News:Healthy planet, places and people at risk 2Health News:Government restrictions on weight loss surgeries limit access for poor, underinsured patients 2Health News:Government restrictions on weight loss surgeries limit access for poor, underinsured patients 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 4Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 5Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 6Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 7Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 8Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 9Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 11Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 12Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 13Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 14Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 15Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 16
... 30° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
The Chalam Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens. This lens was developed with K.V. Chalam,...
... somewhat higher magnification and increased stereopsis, the ... detailed visualization to the equatorial regions. The ... diabetics and in membrane peeling in proliferative ... Sterilizable Lenses The ACS Vitrectomy Lenses from ...
... visualization of virtually the entire retina including ... of the lens on the eye. It ... giant retinal tears, diagnosing and treating anterior ... retina in a vitreous cavity filled with ...
Medicine Products: